ATHIRA PHARMA INC (ATHA) Fundamental Analysis & Valuation

NASDAQ:ATHA • US04746L2034

Current stock price

6.75 USD
-0.44 (-6.12%)
At close:
6.9496 USD
+0.2 (+2.96%)
After Hours:

This ATHA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. ATHA Profitability Analysis

1.1 Basic Checks

  • ATHA had negative earnings in the past year.
  • ATHA had a negative operating cash flow in the past year.
  • ATHA had negative earnings in each of the past 5 years.
  • In the past 5 years ATHA always reported negative operating cash flow.
ATHA Yearly Net Income VS EBIT VS OCF VS FCFATHA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

  • The Return On Assets of ATHA (-125.61%) is worse than 81.77% of its industry peers.
  • ATHA has a worse Return On Equity (-140.83%) than 69.27% of its industry peers.
Industry RankSector Rank
ROA -125.61%
ROE -140.83%
ROIC N/A
ROA(3y)-91.8%
ROA(5y)-59.81%
ROE(3y)-115.75%
ROE(5y)-74.32%
ROIC(3y)N/A
ROIC(5y)N/A
ATHA Yearly ROA, ROE, ROICATHA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 -200 -400

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for ATHA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ATHA Yearly Profit, Operating, Gross MarginsATHA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. ATHA Health Analysis

2.1 Basic Checks

  • The number of shares outstanding for ATHA has been increased compared to 1 year ago.
  • The number of shares outstanding for ATHA has been increased compared to 5 years ago.
  • ATHA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
ATHA Yearly Shares OutstandingATHA Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M
ATHA Yearly Total Debt VS Total AssetsATHA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

  • ATHA has an Altman-Z score of -18.42. This is a bad value and indicates that ATHA is not financially healthy and even has some risk of bankruptcy.
  • ATHA has a Altman-Z score of -18.42. This is amonst the worse of the industry: ATHA underperforms 81.77% of its industry peers.
  • There is no outstanding debt for ATHA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -18.42
ROIC/WACCN/A
WACCN/A
ATHA Yearly LT Debt VS Equity VS FCFATHA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M 300M

2.3 Liquidity

  • A Current Ratio of 9.70 indicates that ATHA has no problem at all paying its short term obligations.
  • Looking at the Current ratio, with a value of 9.70, ATHA is in the better half of the industry, outperforming 79.17% of the companies in the same industry.
  • ATHA has a Quick Ratio of 9.70. This indicates that ATHA is financially healthy and has no problem in meeting its short term obligations.
  • ATHA's Quick ratio of 9.70 is fine compared to the rest of the industry. ATHA outperforms 79.17% of its industry peers.
Industry RankSector Rank
Current Ratio 9.7
Quick Ratio 9.7
ATHA Yearly Current Assets VS Current LiabilitesATHA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. ATHA Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 66.04% over the past year.
EPS 1Y (TTM)66.04%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%77.6%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to grow by 25.82% on average over the next years. This is a very strong growth
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y73.83%
EPS Next 2Y34.35%
EPS Next 3Y25.82%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ATHA Yearly Revenue VS EstimatesATHA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 10K 20K 30K 40K 50K
ATHA Yearly EPS VS EstimatesATHA Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 -10 -20 -30

More info and screens

Find the best growth stocksShow best growing peers

1

4. ATHA Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for ATHA. In the last year negative earnings were reported.
  • Also next year ATHA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ATHA Price Earnings VS Forward Price EarningsATHA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ATHA Per share dataATHA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 -10

4.3 Compensation for Growth

  • A more expensive valuation may be justified as ATHA's earnings are expected to grow with 25.82% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y34.35%
EPS Next 3Y25.82%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. ATHA Dividend Analysis

5.1 Amount

  • No dividends for ATHA!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ATHA Fundamentals: All Metrics, Ratios and Statistics

ATHIRA PHARMA INC

NASDAQ:ATHA (1/9/2026, 8:00:00 PM)

After market: 6.9496 +0.2 (+2.96%)

6.75

-0.44 (-6.12%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-06
Earnings (Next)02-25
Inst Owners33.46%
Inst Owner Change251.21%
Ins Owners3.33%
Ins Owner Change1.02%
Market Cap26.59M
Revenue(TTM)N/A
Net Income(TTM)-37.72M
Analysts45.71
Price Target4.08 (-39.56%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-16.52%
Min EPS beat(2)-35%
Max EPS beat(2)1.96%
EPS beat(4)3
Avg EPS beat(4)-3.44%
Min EPS beat(4)-35%
Max EPS beat(4)13.23%
EPS beat(8)6
Avg EPS beat(8)3.86%
EPS beat(12)8
Avg EPS beat(12)3.02%
EPS beat(16)12
Avg EPS beat(16)4.55%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)700%
EPS NQ rev (1m)15.76%
EPS NQ rev (3m)15.76%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.99
P/tB 0.99
EV/EBITDA N/A
EPS(TTM)-9.68
EYN/A
EPS(NY)-4.94
Fwd EYN/A
FCF(TTM)-13.29
FCFYN/A
OCF(TTM)-13.29
OCFYN/A
SpS0
BVpS6.8
TBVpS6.8
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -125.61%
ROE -140.83%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-91.8%
ROA(5y)-59.81%
ROE(3y)-115.75%
ROE(5y)-74.32%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 9.7
Quick Ratio 9.7
Altman-Z -18.42
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)56.3%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)66.04%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%77.6%
EPS Next Y73.83%
EPS Next 2Y34.35%
EPS Next 3Y25.82%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y64.89%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year31.25%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y42.12%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y41.92%
OCF growth 3YN/A
OCF growth 5YN/A

ATHIRA PHARMA INC / ATHA Fundamental Analysis FAQ

What is the fundamental rating for ATHA stock?

ChartMill assigns a fundamental rating of 2 / 10 to ATHA.


What is the valuation status of ATHIRA PHARMA INC (ATHA) stock?

ChartMill assigns a valuation rating of 1 / 10 to ATHIRA PHARMA INC (ATHA). This can be considered as Overvalued.


What is the profitability of ATHA stock?

ATHIRA PHARMA INC (ATHA) has a profitability rating of 0 / 10.


What is the financial health of ATHIRA PHARMA INC (ATHA) stock?

The financial health rating of ATHIRA PHARMA INC (ATHA) is 6 / 10.


Can you provide the expected EPS growth for ATHA stock?

The Earnings per Share (EPS) of ATHIRA PHARMA INC (ATHA) is expected to grow by 73.83% in the next year.